This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by PETRAGLIA, F. Articles by SEVERI, F. Search for Related Content PubMed PubMed Citation Articles by PETRAGLIA, F. Articles by SEVERI, F.

Impairment of the Opioidergic Control of Luteinizing Hormone Secretion in Turner's Syndrome: Lack of Effect of Gonadal Steroid Therapy^*

Department of Obstetrics and Gynecology, University of Modena School of Medicine Modena
The Department of Pediatrics, University of Pavia School of Medicine (D.L., M.M., F.S.) Pavia
The Department of Pediatrics, University of Parma School of Medicine (S.B.) Parma, Italy

Address all correspondence and requests for reprints to: Felice Petraglia, M.D., Department of Obstetric and Gynecology, University of Modena School of Medicine, Via del Pozzo 71,41100 Modena, Italy.

We studied the activity of endogenous opioid peptides in regulating LH secretion in patients with Turner's syndrome. To do so, we determined the LH secretory response to opiate receptor blockade by naloxone (0.08 mg/kg BW, iv) in 17 patients (age range, 9–23 yr). Eight patients were untreated (3 of whom had had spontaneous menarche), and 9 patients were taking ethinyl estradiol/medroxyprogesterone acetate treatment (5 of these patients were also studied before treatment). In addition, the plasma LH responses to GnRH (50 µg, iv) and placebo were determined in the patients as well as in 13 age-matched normal girls (6 prepubertal and 7 pubertal). Naloxone did not increase plasma LH levels in the amenorrheic untreated and treated patients with Turner's syndrome. However, in the 3 patients who had had spontaneous menarche and in normal pubertal girls naloxone increased plasma LH levels. GnRH was effective to the same extent in the patients and normal subjects. These results indicate that in patients with Turner's syndrome the opioidergic inhibition of LH secretion is impaired and is not restored by gonadal steroid replacement therapy. Moreover, the normal plasma LH responses to naloxone in the spontaneously menstruating patients with Turner's syndrome indicate both the clinical variability of this syndrome and the participation of endogenous opioid peptides in the regulation of normal menstrual function.

^* This work was supported in part by the Consiglio Nazionale delle Ricerche, Gruppo Endocrinologia.

Received August 24, 1987.